National multicenter trial opens to study immunitybio's tri-ad5 cancer vaccines plus n-803 to prevent cancer in people with lynch syndrome

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced the opening of a clinical trial to study its investigational tri-ad5 vaccine combination (adenovirus 5 cea/muc1/brachyury) together with its il-15 superagonist n-803, an immune-enhancer, for people with a hereditary condition known as lynch syndrome. this phase 2b trial (nct05419011) sponsored by the national cancer institute, part of the national institutes of health,.
IBRX Ratings Summary
IBRX Quant Ranking